2019年ACR/EULAR IgG4相关疾病分类标准在中国大型队列中的外部验证
该研究在中国队列中外部验证2019年ACR/EULAR IgG4相关疾病分类标准,共纳入875例IgG4-RD和302例非IgG4-RD病例,以专家临床判断为金标准。结果显示该标准敏感度76.6%(95%CI 73.8%–79.4%),特异度98.0%(96.0%–99.4%),AUC 0.873(0.857–0.889)。作者结论认为该标准特异度突出、敏感度良好,2020年RCD标准有助于诊断以孤立器官(尤其非常见部位)受累为表现的IgG4-RD。
要点
- 2019年ACR/EULAR分类标准在中国队列中敏感度76.6%(95%CI 73.8%–79.4%),特异度98.0%(96.0%–99.4%),AUC 0.873(0.857–0.889)。
- 假阴性病例血清IgG4水平显著更低、具有病理信息者更少,非常见器官受累频率高于真阳性病例。
- 2019年ACR/EULAR分类标准判为阴性而2020年RCD标准判为「确诊」的病例,非常见器官受累更多。
核心结论
- 作者结论认为2019年ACR/EULAR IgG4-RD分类标准在真实临床实践中特异度突出、敏感度良好。
- 作者结论认为2020年RCD标准有助于诊断以孤立器官(尤其非常见部位)受累为表现的IgG4-RD。
研究设计与样本
- 在中国队列中外部验证2019年ACR/EULAR IgG4-RD分类标准的性能,并与2020年RCD标准比较。
- 共纳入875例IgG4-RD和302例非IgG4-RD病例,非IgG4-RD包括213例模仿者和89例其他疾病患者。
- 以专家临床判断作为IgG4-RD诊断的金标准,评估敏感度、特异度和AUC。
主要发现
- 2019年ACR/EULAR分类标准在总体队列中敏感度76.6%(95%CI 73.8%–79.4%),特异度98.0%(96.0%–99.4%),AUC 0.873(0.857–0.889)。
- 2019年ACR/EULAR分类标准判为假阴性的病例较真阳性病例血清IgG4水平显著更低、具有病理信息者更少、非常见器官受累频率更高。
- 被2019年ACR/EULAR分类标准判为阴性而2020年RCD标准判为「确诊」的病例,非常见器官受累更多。
关键数值与推荐
- 2019年ACR/EULAR分类标准:敏感度76.6%(95%CI 73.8%–79.4%),特异度98.0%(96.0%–99.4%),AUC 0.873(0.857–0.889)。
- 2020年RCD标准:原文报告有助于诊断以孤立器官(尤其非常见部位)受累为表现的IgG4-RD。
临床怎么用
- 作者认为2019年ACR/EULAR IgG4-RD分类标准在真实临床实践中特异度突出、敏感度良好。
- 作者认为2020年RCD标准有助于诊断以孤立器官(尤其非常见部位)受累为表现的IgG4-RD。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To externally validate the performance of the 2019 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for IgG4-related disease (IgG4-RD) within a cohort from China and to compare the criteria with the 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. METHODS: This study included 875 IgG4-RD and 302 non-IgG4-RD cases (213 mimickers and 89 patients with other diseases). Using expert clinical judgment as the gold standard for diagnosis of IgG4-RD, the performance (sensitivity, specificity, area under the curve (AUC) of the 2019 ACR/EULAR criteria for IgG4-RD was evaluated. We also compared it with the 2020 RCD criteria. RESULTS: The 2019 ACR/EULAR classification criteria had a sensitivity of 76.6% (95% CI: 73.8% to 79.4%) and a specificity of 98.0% (96.0%-99.4%), an AUC of 0.873 (0.857-0.889) in the overall cohort. Those false negative cases under the 2019 ACR/EULAR classification criteria had significantly lower levels of serum IgG4, and fewer had pathological information, with a higher frequency in the involvement of those uncommon organs compared with the true positive cases. The cases judged as negative by the 2019 ACR/EULAR classification criteria yet judged as "definite" by the 2020 RCD criteria had more involvement of uncommon organs. CONCLUSIONS: The 2019 ACR/EULAR classification criteria for IgG4-RD show outstanding specificity and good sensitivity in real-world clinical practice. The 2020 RCD criteria are helpful for the diagnosis of IgG4-RD in clinical scenarios where IgG4-RD presents as involving an isolated organ, especially the unusual sites.
引用
- Liu Z, Nie Y, Peng Y, et al. The external validation of the 2019 ACR/EULAR classification criteria for IgG4-related disease in a large cohort from China. Semin Arthritis Rheum. 2023. PMID: 37167774. doi:10.1016/j.semarthrit.2023.152202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。